David R. Jones
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David R. Jones has a total of 810 co-authors. Here are the top co-authors by number of shared publications:
Kay See Tan
43 shared publicationsPrasad S. Adusumilli
Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, United States
38 shared publications- Daniela Molena
Memorial Sloan Kettering Cancer Center, New York, NY
30 shared publications - Charles M. Rudin
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
25 shared publications - Abraham J. Wu
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
22 shared publications - Geoffrey Yuyat Ku
Memorial Sloan Kettering Cancer Center
21 shared publications
Latest Publications
- Open Access
A Prospective Assessment of Near-Infrared Image-Guided Sentinel Lymph Node Identification in Esophageal and Esophagogastric Junction Cancer
Objective: To evaluate the feasibility of sentinel lymph node (SLN) identification in distal esophageal and esophagogastric junction (EGJ) adenocarcinoma and determine whether the SLN concept applies to this disease. Methods: Patients undergoing esophagectomy for clinical stage I-IVA esophageal and EGJ adenocarcinoma underwent SLN mapping by near-infrared detection of indocyanine green (ICG) injected via endoscopy before esophagectomy. Lymphatic drainage patterns were recorded, and the first identified nodes (SLNs) were harvested. Standard esophagectomy and lymphadenectomy were performed. SLN status was compared with overall nodal status. Results: Of 90 included patients, 77 received ICG; SLN mapping was successful in 64 (83%). Ten patients had two SLN stations identified; the remainder had one. The most common SLN location was along the left gastric artery (36/74 [48%]), followed by the paracardial (17/74 [23%]) and periesophageal (15/74 [20%]) stations. Seven patients had SLNs positive for metastasis (in one, the SLN was the only positive node; in the rest, metastatic nodes were identified in the same or other stations). Of the 57 patients with negative SLNs, 11 (19%) had ≥1 positive node in the same or different nodal station. The false-negative rate was 61.1%. Conclusions: SLN mapping with ICG is feasible in patients with distal esophageal and EGJ adenocarcinoma, with a high rate of successful node identification. Occult nodal metastasis in patients with negative SLNs limits the reliability of SLN assessment as a determinant for selective lymphadenectomy.
Open AccessA Prospective Assessment of Near-Infrared Image-Guided Sentinel Lymph Node Identification in Esophageal and Esophagogastric Junction Cancer
Objective: To evaluate the feasibility of sentinel lymph node (SLN) identification in distal esophageal and esophagogastric junction (EGJ) adenocarcinoma and determine whether the SLN concept applies to this disease. Methods: Patients undergoing esophagectomy for clinical stage I-IVA esophageal and EGJ adenocarcinoma underwent SLN mapping by near-infrared detection of indocyanine green (ICG) injected via endoscopy before esophagectomy. Lymphatic drainage patterns were recorded, and the first identified nodes (SLNs) were harvested. Standard esophagectomy and lymphadenectomy were performed. SLN status was compared with overall nodal status. Results: Of 90 included patients, 77 received ICG; SLN mapping was successful in 64 (83%). Ten patients had two SLN stations identified; the remainder had one. The most common SLN location was along the left gastric artery (36/74 [48%]), followed by the paracardial (17/74 [23%]) and periesophageal (15/74 [20%]) stations. Seven patients had SLNs positive for metastasis (in one, the SLN was the only positive node; in the rest, metastatic nodes were identified in the same or other stations). Of the 57 patients with negative SLNs, 11 (19%) had ≥1 positive node in the same or different nodal station. The false-negative rate was 61.1%. Conclusions: SLN mapping with ICG is feasible in patients with distal esophageal and EGJ adenocarcinoma, with a high rate of successful node identification. Occult nodal metastasis in patients with negative SLNs limits the reliability of SLN assessment as a determinant for selective lymphadenectomy.
- 16 July 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- p. JCO2502517
Durvalumab With Radiation Therapy in Patients With Inoperable Locally Advanced Non–Small Cell Lung Cancer Ineligible for Concurrent Chemoradiotherapy (DART)
PURPOSE: Concurrent platinum-based chemotherapy and radiation therapy (cCRT) followed by consolidative durvalumab is the standard of care (SoC) for fit patients with inoperable, locally advanced non–small cell lung cancer (LA-NSCLC). However, no SoC exists for patients who are cCRT-ineligible because of age, comorbidities, or frailty. Here, we investigated the efficacy and adverse events (AEs) of concurrent and consolidative durvalumab with definitive radiation therapy (RT) without chemotherapy. METHODS: In this multicenter, single-arm, prospective phase II study, patients received conventionally fractionated RT plus concurrent and consolidative durvalumab (1,500 mg fixed dose once every 4 weeks) for up to 12 months. The primary end point was 2-year progression-free survival (PFS) of 36% compared with historical results of 20% with sequential CRT (86% power). Additional end points included overall survival (OS) and cancer-specific survival (CSS). RESULTS: Fifty-eight patients (median age 82 years [IQR, 76-86]; 16 [28%] PD-L1–negative; eight [14%] Eastern Cooperative Oncology Group [ECOG] score 2; 46 [79%] ECOG score 1; four [7%] ECOG score 0) were treated per protocol. The study met its primary end point with a 2-year PFS of 39% (one-sided CI, 29 to 100) and a 2-year OS of 54%. Better performance status and PD-L1 positivity were associated with improved PFS; better ECOG was associated with improved OS; PD-L1 positivity was associated with better CSS. Grade 3/4 treatment-related AEs occurred in 12 (21%) patients. Grade 5 AEs occurred in four (7%) patients (radiation pneumonitis (n = 2) and cardiac arrest (n = 2)). Durvalumab was discontinued early because of AEs in 18 (31%) patients. CONCLUSION: Thoracic RT with concurrent and consolidative durvalumab is a promising treatment option for cCRT-ineligible patients with LA-NSCLC, demonstrating better PFS with a favorable safety profile compared with historical controls.
- 16 July 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- p. JCO2502517
Durvalumab With Radiation Therapy in Patients With Inoperable Locally Advanced Non–Small Cell Lung Cancer Ineligible for Concurrent Chemoradiotherapy (DART)
PURPOSE: Concurrent platinum-based chemotherapy and radiation therapy (cCRT) followed by consolidative durvalumab is the standard of care (SoC) for fit patients with inoperable, locally advanced non–small cell lung cancer (LA-NSCLC). However, no SoC exists for patients who are cCRT-ineligible because of age, comorbidities, or frailty. Here, we investigated the efficacy and adverse events (AEs) of concurrent and consolidative durvalumab with definitive radiation therapy (RT) without chemotherapy. METHODS: In this multicenter, single-arm, prospective phase II study, patients received conventionally fractionated RT plus concurrent and consolidative durvalumab (1,500 mg fixed dose once every 4 weeks) for up to 12 months. The primary end point was 2-year progression-free survival (PFS) of 36% compared with historical results of 20% with sequential CRT (86% power). Additional end points included overall survival (OS) and cancer-specific survival (CSS). RESULTS: Fifty-eight patients (median age 82 years [IQR, 76-86]; 16 [28%] PD-L1–negative; eight [14%] Eastern Cooperative Oncology Group [ECOG] score 2; 46 [79%] ECOG score 1; four [7%] ECOG score 0) were treated per protocol. The study met its primary end point with a 2-year PFS of 39% (one-sided CI, 29 to 100) and a 2-year OS of 54%. Better performance status and PD-L1 positivity were associated with improved PFS; better ECOG was associated with improved OS; PD-L1 positivity was associated with better CSS. Grade 3/4 treatment-related AEs occurred in 12 (21%) patients. Grade 5 AEs occurred in four (7%) patients (radiation pneumonitis (n = 2) and cardiac arrest (n = 2)). Durvalumab was discontinued early because of AEs in 18 (31%) patients. CONCLUSION: Thoracic RT with concurrent and consolidative durvalumab is a promising treatment option for cCRT-ineligible patients with LA-NSCLC, demonstrating better PFS with a favorable safety profile compared with historical controls.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (16) , 1540-1552
Metastatic Trajectories in Non–Small Cell Lung Cancer Guide Local and Systemic Therapies
Advances in systemic therapy have improved outcomes for metastatic non–small cell lung cancer (NSCLC), yet resistance and progression remain nearly universal. Local therapies such as radiotherapy, surgery, and image-guided ablation can extend disease control in selected patients, but existing classifications—including dynamic models of oligometastatic disease—assign a single state per patient and do not capture lesion-level heterogeneity. We introduce the concept of metastatic trajectories —the spatiotemporal dynamics of response and progression across lesions, organs, and patients—as a framework to characterize intrapatient heterogeneity and inform adaptive treatment strategies. Dimensions of metastatic trajectories include the magnitude and homogeneity of response, mechanisms of resistance, organotropism, and the pattern, site, extent, and pace of progression. This framework shifts the focus from overall disease states to individual lesion behavior over time, enabling reactive strategies based on observed trajectories and anticipatory strategies based on predicted ones. We review the biological foundations of intrapatient heterogeneity—including genomic diversification, nongenetic plasticity, and tumor-microenvironmental adaptation—that drive divergent lesion evolution and treatment response. Emerging biomarkers such as circulating tumor DNA and radiomic signatures, together with integrative genomic and functional imaging approaches, may allow tracking and prediction of trajectory evolution. Standardized reporting parameters are proposed to ensure consistent documentation and facilitate validation across studies. Integrating trajectory-based assessment into clinical practice could refine patient selection for local and systemic therapy, enable biology-informed adaptation of treatment timing and intensity, and provide a foundation for next-generation clinical trials aimed at precision management of metastatic NSCLC.
- 1 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (16) , 1540-1552
Metastatic Trajectories in Non–Small Cell Lung Cancer Guide Local and Systemic Therapies
Advances in systemic therapy have improved outcomes for metastatic non–small cell lung cancer (NSCLC), yet resistance and progression remain nearly universal. Local therapies such as radiotherapy, surgery, and image-guided ablation can extend disease control in selected patients, but existing classifications—including dynamic models of oligometastatic disease—assign a single state per patient and do not capture lesion-level heterogeneity. We introduce the concept of metastatic trajectories —the spatiotemporal dynamics of response and progression across lesions, organs, and patients—as a framework to characterize intrapatient heterogeneity and inform adaptive treatment strategies. Dimensions of metastatic trajectories include the magnitude and homogeneity of response, mechanisms of resistance, organotropism, and the pattern, site, extent, and pace of progression. This framework shifts the focus from overall disease states to individual lesion behavior over time, enabling reactive strategies based on observed trajectories and anticipatory strategies based on predicted ones. We review the biological foundations of intrapatient heterogeneity—including genomic diversification, nongenetic plasticity, and tumor-microenvironmental adaptation—that drive divergent lesion evolution and treatment response. Emerging biomarkers such as circulating tumor DNA and radiomic signatures, together with integrative genomic and functional imaging approaches, may allow tracking and prediction of trajectory evolution. Standardized reporting parameters are proposed to ensure consistent documentation and facilitate validation across studies. Integrating trajectory-based assessment into clinical practice could refine patient selection for local and systemic therapy, enable biology-informed adaptation of treatment timing and intensity, and provide a foundation for next-generation clinical trials aimed at precision management of metastatic NSCLC.
- Open Access
- 1 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (5) , e2500597
Multimodal Impact of Number of Metastases and Genetic Alterations on Survival in Metastatic Non–Small Cell Lung Cancer
PURPOSE: Oligometastatic disease (OMD) is an intermediate state of metastatic disease in which metastasis-directed therapy (MDT) may improve outcomes. The classification of OMD is inconsistent, typically defined by number of metastases without considering tumor biologic characteristics. To help optimize patient selection for MDT, we analyzed integrated genomic sequencing results from patients with metastatic non–small cell lung cancer (NSCLC). MATERIALS AND METHODS: Patients with metastatic NSCLC who had molecular sequencing through a validated institutional assay (MSK-IMPACT) were included. The number and location of metastases were manually annotated (assigned 1-10 and >10). Individual gene variant scores were analyzed by gene length and patient mutation burden. Analysis was completed in R and included maximally selected rank statistics, agglomerative hierarchical clustering, and the chi-square test for independence. RESULTS: In total, 844 patients had clinical data, tissue sequencing, and annotated imaging for analysis. Of these, 635 had >10 metastases (75.2%), and 209 had 1-10 metastases (24.8%). The cutpoint that maximized overall survival (OS) was four metastases, and six mutation signatures were identified. For patients with 1-4 metastases, TERT and KMT2D had inferior OS, while for those with ≥5 metastases, EGFR , ALK , and TBX3 had superior OS. CONCLUSION: The cutpoint that maximized difference in OS was four metastases, but incorporating genetic alteration information modified this criterion. These findings were proof of principle that integrating multimodal data beyond number of lesions can better identify patients with metastatic NSCLC who may be candidates for MDT.
- 1 May 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (5) , e2500597
Open AccessMultimodal Impact of Number of Metastases and Genetic Alterations on Survival in Metastatic Non–Small Cell Lung Cancer
PURPOSE: Oligometastatic disease (OMD) is an intermediate state of metastatic disease in which metastasis-directed therapy (MDT) may improve outcomes. The classification of OMD is inconsistent, typically defined by number of metastases without considering tumor biologic characteristics. To help optimize patient selection for MDT, we analyzed integrated genomic sequencing results from patients with metastatic non–small cell lung cancer (NSCLC). MATERIALS AND METHODS: Patients with metastatic NSCLC who had molecular sequencing through a validated institutional assay (MSK-IMPACT) were included. The number and location of metastases were manually annotated (assigned 1-10 and >10). Individual gene variant scores were analyzed by gene length and patient mutation burden. Analysis was completed in R and included maximally selected rank statistics, agglomerative hierarchical clustering, and the chi-square test for independence. RESULTS: In total, 844 patients had clinical data, tissue sequencing, and annotated imaging for analysis. Of these, 635 had >10 metastases (75.2%), and 209 had 1-10 metastases (24.8%). The cutpoint that maximized overall survival (OS) was four metastases, and six mutation signatures were identified. For patients with 1-4 metastases, TERT and KMT2D had inferior OS, while for those with ≥5 metastases, EGFR , ALK , and TBX3 had superior OS. CONCLUSION: The cutpoint that maximized difference in OS was four metastases, but incorporating genetic alteration information modified this criterion. These findings were proof of principle that integrating multimodal data beyond number of lesions can better identify patients with metastatic NSCLC who may be candidates for MDT.
- Open Access
- 19 April 2026
- Published by Elsevier in Lung Cancer
- Vol. 216, 109420
Utilization of invasive mediastinal nodal staging and prevalence of occult nodal disease in patients with synchronous primary lung cancers
- 19 April 2026
- Published by Elsevier in Lung Cancer
- Vol. 216, 109420
Open AccessUtilization of invasive mediastinal nodal staging and prevalence of occult nodal disease in patients with synchronous primary lung cancers
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (4) , e2501069
Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal Adenocarcinoma
PURPOSE: We sought to characterize the genomic landscape of gastroesophageal adenocarcinoma (GEA) using next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA), compare the genomic profile to tissue NGS, and determine the association of circulating tumor DNA (ctDNA) detection with clinical outcomes. METHODS: In this prospective biospecimen-collection study (2017-2022), cfDNA was analyzed using a clinically validated 129-gene tumor-informed NGS assay Memorial Sloan Kettering-Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS); tissue-NGS was performed using Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets. RESULTS: In total, 169 patients with GEA underwent baseline molecular profiling of cfDNA; 93 had localized disease, 55 had untreated metastatic disease, and 21 had progressive metastatic disease. The frequency of the most common alterations was similar between platforms, although copy-number alterations were detected less frequently in plasma than in tissue (10% v 40%; P < .001). Matched-tumor NGS was conducted in 154 patients (91%). Baseline ctDNA detection and on-treatment clearance were associated with improved overall survival and recurrence-free survival in patients with localized disease and progression-free survival in patients with metastatic disease. Baseline ctDNA detection was a stronger predictor of overall survival than American Joint Committee on Cancer (AJCC) clinical stage and positively predicted lymph node metastasis in 87% of cases. Trends in variant allele fractions correlated with pathologic responses to neoadjuvant therapy more closely than fluorodeoxyglucose-positron emission tomography standard uptake values. Persistence or resurgence of ctDNA was associated with worse survival and forecasted recurrent disease a median of 7 months sooner than imaging. CONCLUSION: cfDNA analysis using MSK-ACCESS in patients with GEA is a valuable adjunctive clinical tool that enhances molecular profiling, prognostication, treatment response assessment, and detection of recurrent disease in conjunction with tissue NGS, imaging, and AJCC clinical staging criteria.
- 1 April 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (4) , e2501069
Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal Adenocarcinoma
PURPOSE: We sought to characterize the genomic landscape of gastroesophageal adenocarcinoma (GEA) using next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA), compare the genomic profile to tissue NGS, and determine the association of circulating tumor DNA (ctDNA) detection with clinical outcomes. METHODS: In this prospective biospecimen-collection study (2017-2022), cfDNA was analyzed using a clinically validated 129-gene tumor-informed NGS assay Memorial Sloan Kettering-Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS); tissue-NGS was performed using Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets. RESULTS: In total, 169 patients with GEA underwent baseline molecular profiling of cfDNA; 93 had localized disease, 55 had untreated metastatic disease, and 21 had progressive metastatic disease. The frequency of the most common alterations was similar between platforms, although copy-number alterations were detected less frequently in plasma than in tissue (10% v 40%; P < .001). Matched-tumor NGS was conducted in 154 patients (91%). Baseline ctDNA detection and on-treatment clearance were associated with improved overall survival and recurrence-free survival in patients with localized disease and progression-free survival in patients with metastatic disease. Baseline ctDNA detection was a stronger predictor of overall survival than American Joint Committee on Cancer (AJCC) clinical stage and positively predicted lymph node metastasis in 87% of cases. Trends in variant allele fractions correlated with pathologic responses to neoadjuvant therapy more closely than fluorodeoxyglucose-positron emission tomography standard uptake values. Persistence or resurgence of ctDNA was associated with worse survival and forecasted recurrent disease a median of 7 months sooner than imaging. CONCLUSION: cfDNA analysis using MSK-ACCESS in patients with GEA is a valuable adjunctive clinical tool that enhances molecular profiling, prognostication, treatment response assessment, and detection of recurrent disease in conjunction with tissue NGS, imaging, and AJCC clinical staging criteria.
- 31 March 2026
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 172 (3) , 708-714
Scholarship in cardiothoracic surgery: Via minus trita
- 31 March 2026
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 172 (3) , 708-714
Scholarship in cardiothoracic surgery: Via minus trita
- 7 March 2026
- Published by Elsevier in Thoracic Surgery Clinics
- Vol. 36 (1) , e1-e9
Do Stage I Patients Need Systemic Therapy?
- 7 March 2026
- Published by Elsevier in Thoracic Surgery Clinics
- Vol. 36 (1) , e1-e9
Do Stage I Patients Need Systemic Therapy?
- Open Access
Prognosis from Pixels: A Vendor-Protocol-Specific CT-Radiomics Model for Predicting Recurrence in Resected Lung Adenocarcinoma
Background: Radiomics can provide quantitative descriptors of tumor phenotype, but translation is often limited by feature instability across scanners and protocols. We aimed to develop and internally validate a protocol-specific CT-radiomics model using preoperative imaging to predict 5-year recurrence in patients with stage I lung adenocarcinoma after complete surgical resection. Methods: The retrospective study included 270 patients with completely resected stage I lung adenocarcinoma from January 2010–December 2021, among whom 23 (8.5%) experienced recurrence within five years. Radiomic features were extracted from routine preoperative CT scans. After preprocessing to remove highly constant and highly correlated features, the Synthetic Minority Over-sampling Technique addressed class imbalance in the training set. Recursive Feature Elimination identified the most predictive radiomic features. An XGBoost classifier was trained using optimized hyperparameters identified through RandomizedSearchCV with cross-validation. Model performance was evaluated using the ROC curve and predictive metrics. Results: Five radiomic features differed significantly between recurrence groups (p = 0.007 to <0.001): Shape Sphericity, first-order 90Percentile, GLCM Autocorrelation, GLCM Cluster Shade, and GLDM Large Dependence Low Gray Level Emphasis. The radiomics model showed excellent discriminatory ability with AUC values of 0.99 (95% CI: 0.98–1.00), 0.97 (95% CI: 0.91–1.00), and 0.96 (95% CI: 0.85–1.00) on the training, validation, and test sets, respectively. On the test set, the model achieved sensitivity of 100% (95% CI: 51–100%), specificity of 94% (95% CI: 81–98%), PPV of 67% (95% CI: 30–90%), NPV of 100% (95% CI: 90–100%), and overall accuracy of 95% (95% CI: 83–99%). Conclusions: Under protocol-homogeneous imaging conditions, CT radiomics accurately predicted recurrence in patients with completely resected stage I lung adenocarcinoma. External multi-vendor validation is needed before broader deployment.
Open AccessPrognosis from Pixels: A Vendor-Protocol-Specific CT-Radiomics Model for Predicting Recurrence in Resected Lung Adenocarcinoma
Background: Radiomics can provide quantitative descriptors of tumor phenotype, but translation is often limited by feature instability across scanners and protocols. We aimed to develop and internally validate a protocol-specific CT-radiomics model using preoperative imaging to predict 5-year recurrence in patients with stage I lung adenocarcinoma after complete surgical resection. Methods: The retrospective study included 270 patients with completely resected stage I lung adenocarcinoma from January 2010–December 2021, among whom 23 (8.5%) experienced recurrence within five years. Radiomic features were extracted from routine preoperative CT scans. After preprocessing to remove highly constant and highly correlated features, the Synthetic Minority Over-sampling Technique addressed class imbalance in the training set. Recursive Feature Elimination identified the most predictive radiomic features. An XGBoost classifier was trained using optimized hyperparameters identified through RandomizedSearchCV with cross-validation. Model performance was evaluated using the ROC curve and predictive metrics. Results: Five radiomic features differed significantly between recurrence groups (p = 0.007 to <0.001): Shape Sphericity, first-order 90Percentile, GLCM Autocorrelation, GLCM Cluster Shade, and GLDM Large Dependence Low Gray Level Emphasis. The radiomics model showed excellent discriminatory ability with AUC values of 0.99 (95% CI: 0.98–1.00), 0.97 (95% CI: 0.91–1.00), and 0.96 (95% CI: 0.85–1.00) on the training, validation, and test sets, respectively. On the test set, the model achieved sensitivity of 100% (95% CI: 51–100%), specificity of 94% (95% CI: 81–98%), PPV of 67% (95% CI: 30–90%), NPV of 100% (95% CI: 90–100%), and overall accuracy of 95% (95% CI: 83–99%). Conclusions: Under protocol-homogeneous imaging conditions, CT radiomics accurately predicted recurrence in patients with completely resected stage I lung adenocarcinoma. External multi-vendor validation is needed before broader deployment.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer
Supplementary Data from Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer